-
Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Modifier Gene Therapy
19 Apr 2024 11:13 GMT
… ArMaDa clinical trial. “Currently we have two FDA approved, anti … developing AAV-RORA as a one-time gene therapy for the treatment … has the potential to treat multiple retinal diseases with … are advancing research in infectious diseases to support public health …
-
Study highlights heavy global burden of infectious diseases
19 Apr 2024 00:05 GMT
… Infectious Diseases highlights the substantial impact of infectious diseases … further research in drug development, vaccinology, and … leading to increased treatment costs, prolonged hospital … an accompanying commentary, infectious diseases experts from South …
-
Nykode Therapeutics Initiates Phase 2 Trial of VB10.16 in Second Line HPV16-Positive Cervical Cancer
19 Apr 2024 05:00 GMT
… “Initiating the VB10.16 trial for HPV16-positive cervical … vaccine candidate in development for the treatment of human … Regeneron in oncology and infectious diseases. Nykode is also utilizing … to work directly with pharmaceutical organizations and operate …
-
Genovefa (Zenia) Papanicolaou, MD, on Managing Infectious Diseases in Patients Receiving Stem Cell Transplant or Cell Therapy
18 Apr 2024 17:01 GMT
… receiving these treatments are highly vulnerable to infectious diseases.
For the … Papanicolaou, MD, an infectious diseases specialist at Memorial Sloan Kettering … a phase 1 trial of multivirus-specific … to join the Infectious Disease Special Interest Group …
-
Infectious Disease News Digest
18 Apr 2024 16:33 GMT
US Pharm. 2024;49(4):26-29.
Flu Vaccines Likely to Move From Quadrivalent to Trivalent Currently, all influenza vaccines in the United States are quadrivalent, meaning that they protect against four different flu viruses. According to a University of …
-
Paratek Pharmaceuticals Presenting New Data from NUZYRA® (Omadacycline) and Investigator-Initiated Pre-Clinical Studies at European Society of Clinical Microbiology & Infectious Diseases Global (ESCMID Global) 2024
18 Apr 2024 11:30 GMT
… Medical Microbiology and Infectious Diseases, Rotterdam, Netherlands … diagnostics, antimycobacterial drugs, susceptibility testing, treatment & … About Paratek Pharmaceuticals, Inc.
Paratek Pharmaceuticals, Inc. … development of NUZYRA for both the treatment …
-
YS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccine
18 Apr 2024 21:55 GMT
… vaccine, designed to treat patients suffering from chronic … treatment options to chronic HBV patients."
The Phase I clinical trial … biologics for infectious diseases and cancer. It has developed a … experience in the bio-pharmaceutical industry. For more …
-
Texas Biomed researching vaccines and treatments for highly pathogenic avian influenza
18 Apr 2024 21:38 GMT
… them and developing vaccines and treatments well before … resistance to current antiviral drugs," said Martinez-Sobrido … the global community from infectious diseases. Through basic research, … -researching-vaccines-and-treatments-for-highly-pathogenic- …
-
Antibiotic demonstrates non-inferiority to a leading gonorrhoea treatment
18 Apr 2024 22:06 GMT
… oral option for the treatment of gonorrhoea.
New trial results for GSK … gonorrhoea worldwide including drug resistant infections,” Chris Corsico, SVP Development, GSK stated … Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global at the end …
-
Barinthus Bio Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) Infections
18 Apr 2024 20:10 GMT
… -stage biopharmaceutical company developing novel T cell immunotherapeutic … given that the trial was not powered … candidate designed to treat recurrent prostate cancer. … towards delivering treatments for people with infectious diseases, autoimmunity and …